Boehringer Ingelheim will pay a total of up to $365m to acquire its venture fund's portfolio company Amal Therapeutics, an immunotherapy spinout of University of Geneva.

Amal Therapeutics, a Switzerland-based cancer-focused biotechnology spinout from University of Geneva,  yesterday agreed to an acquisition worth up to €325m ($365m) by one of its existing investors, pharmaceutical firm Boehringer Ingelheim.

Boehringer Ingelheim will make an upfront payment of undisclosed size, with the remainder due once contingent clinical, developmental and regulatory milestones are hit. A total of $112m will be paid out if treatments reach certain commercial milestones.

Founded in 2012, Amal Therapeutics is working on peptide-based therapeutic vaccines using…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn